Top

Published in:

01-02-2007

Opa Interacting Protein 5 (OIP5) Is a Novel Cancer-testis Specific Gene in Gastric Cancer

Authors: Yoshito Nakamura, Fumiaki Tanaka, Hisashi Nagahara, Keisuke Ieta, Naotsugu Haraguchi, Koshi Mimori, Atsushi Sasaki, Hiroshi Inoue, Katsuhiko Yanaga, Masaki Mori

Published in: Annals of Surgical Oncology | Issue 2/2007

Abstract

Background

Identification of novel cancer-specific antigens is important for the advancement of immunotherapy. Our aim was to identify cancer-specific genes in gastric cancer.

Methods

Using cDNA microarray analysis, we detected genes overexpressed specifically in gastric cancer cells. The expression levels of selected genes, including OIP5, was confirmed by real time RT-PCR analysis in tumor/normal paired bulk samples of 58 clinical cases. The expression levels of selected genes in normal tissues were also determined with a human total RNA master panel. We also compared the expression status of OIP5 with that of the other known cancer-testis specific genes.

Results

Twenty-two genes were determined to be upregulated in gastric cancer cells. Among these, three genes (CDC6, Exo1, and OIP5) were selected and confirmed to be upregulated in the tumor tissue compared to normal tissue. A human total RNA master panel demonstrated that OIP5, but not Exo1 or CDC6, showed high specificity in testis. Thus OIP5 may be considered a cancer-testis specific gene. In 58 clinical cases of gastric cancer examined, we found OIP5 gene expression in 27 cases (47%). Thirteen of these 27 cases showed no expression of the known cancer specific genes such as MAGE-1, MAGE-3 or NY-ESO-1.

Conclusions

Using a combination of LMD and microarray, we identified OIP5 as a cancer-testis specific gene. Further expression analysis in a set of clinical cases revealed that OIP5 may be a novel immunotherapy target for patients with gastric cancer.

Jemal A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin 2004; 54:8–29PubMedCrossRef

Sadanaga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001; 7:2277–84PubMed

Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46:82–7PubMedCrossRef

Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 2001; 61:2618–24PubMed

van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643–7PubMedCrossRef

Inoue H, Mori M, Honda M, et al. The expression of tumor-rejection antigen ‘MAGE’ genas in human gastric carcinoma. Gastroenterology 1995; 109:1522–5PubMedCrossRef

Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997; 79:206–13PubMedCrossRef

Tanaka F, Fujie T, Tahara K, et al. Induction of antitumor CTLs with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997; 57:4465–8PubMed

Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi T. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer 1999; 80:169–72PubMedCrossRef

10.

Wang Y, Wu XJ, Zhao AL, Yuan YH, Chen YT, Jungbluth AA, et al. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immunol 2004; 4:11

11.

Laura J. van ‘t Veer, Hongyue Dai, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530–6

12.

Quackenbush J. Microarray data normalization and transformation. Nat Genet 2002;32:496–501PubMedCrossRef

13.

Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995; 55:3417–20PubMed

14.

Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res 2005; 11:2889–93PubMedCrossRef

15.

Mashino K, Sadanaga N, Tanaka F, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001; 85:713–20PubMedCrossRef

16.

Jungblunth AA, Stockert E, Chen YT, et al. Monoclonal antibody MA454 reveals a heteroeneous expression pattern of MAGE-1 antigen in formalin-mixed paraffin embedded lung tumours. Br J Cancer 2000; 83:493–7CrossRef

17.

Sadanaga N, Nagashima H, Tahara K, Yoshikawa Y, Mori M. The heterogeneous expression of MAGE-3 protein: difference between primary lesions and metastatic lymph nodes in gastric carcionoma. Oncol Rep 1999; 6:975–7PubMed

18.

Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005; 46:256–69PubMedCrossRef

19.

Ji H, Liu YE, Jia T, et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997; 57:759-–64PubMed

20.

Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 2000; 88:2154–63PubMedCrossRef

21.

El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, Frierson Jr HF, Powell SM. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002; 62:6823–6PubMed

22.

Yanagawa N, Tamura G, Honda T, Endoh M, Nishizuka S, Motoyama T. Demethylation of the synuclein gene CpG Island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res 2004; 10:2447–51PubMedCrossRef

23.

Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci 2002; 7:1356–68CrossRef

24.

Jia T, Liu YE, Liu J, Shi YE. Stimulation of breast cancer invasion and metastasis by synuclein . Cancer Res 1999; 59:742–7PubMed

25.

Pawlak A, Toussaint C, Levy I, Bulle F, Poyard M, Barouki R, Guellaen G. Characterization of a large population of mRNAs from human testis. Genomics 1995; 27:151–8CrossRef

26.

Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 27:199–208CrossRef

27.

Boon K, Edwards JB, Siu IM, et al. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 2003; 22:7687–94PubMedCrossRef

28.

Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004; 10:4307–13PubMedCrossRef

29.

van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998; 102:1376–9PubMedCrossRef

30.

Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen prame is a dominant repressor of retinoic acid receptor signaling. Cell 2005; 122:835–47PubMedCrossRef

31.

Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002; 133:118–23PubMedCrossRef

32.

Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002; 138:89–91PubMedCrossRef

33.

Tajeddine N, Gala JL, Louis M, Van Schoor M, Tombal B, Gailly P. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 2005; 65:7348–55PubMedCrossRef

Title: Opa Interacting Protein 5 (OIP5) Is a Novel Cancer-testis Specific Gene in Gastric Cancer
Authors: Yoshito Nakamura
Fumiaki Tanaka
Hisashi Nagahara
Keisuke Ieta
Naotsugu Haraguchi
Koshi Mimori
Atsushi Sasaki
Hiroshi Inoue
Katsuhiko Yanaga
Masaki Mori
Publication date: 01-02-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-006-9121-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Opa Interacting Protein 5 (OIP5) Is a Novel Cancer-testis Specific Gene in Gastric Cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2007

Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution

Image Guidance during Abdominal Exploration for Recurrent Colorectal Cancer

Complications Associated with Neoadjuvant Radiotherapy in the Multidisciplinary Treatment of Retroperitoneal Sarcomas

Amelioration of Operation-Induced Suppression of Marginating Pulmonary NK Activity using Poly IC: A Potential Approach to Reduce Postoperative Metastasis

Prognostic Score in Gastric Cancer Patients

Lymphatic Drainage of the Peritoneal Space: A Pattern Dependent on Bowel Lymphatics